Gilbert's syndrome is a type of hereditary disease caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene, which leads to decreased UGT1A1 activity. Clinically, it is mainly characterized by increased unconjugated bilirubin and is often considered a benign disease. The incidence rate of Gilbert's syndrome is as high as 5%-10% in the population, and its interaction with commonly used clinical drugs deserves attention. On the one hand, some drugs can enhance or reduce UGT1A1 activity, causing bilirubin levels to decrease or increase. On the other hand, the decrease of UGT1A1 activity can also change part of drug metabolism, increase or reduce drug efficacy, and may cause adverse reactions and even endanger the patient's life in severe conditions. This article summarizes the interactions between common drug metabolism and precautions for drug usage in Gilbert syndrome.
吉尔伯特综合征为遗传性疾病，因尿苷二磷酸葡萄糖醛酸转移酶1A1（UGT1A1）基因发生突变而导致UGT1A1酶活性降低，临床上以非结合胆红素升高为主，常被认作是一种良性疾病。吉尔伯特综合征患病率高达人群的5%～10%，其与临床常用药物间的相互作用值得关注：一方面，部分药物可增强或降低UGT1A1酶活性，引发胆红素水平降低或升高；另一方面，UGT1A1酶活性的降低也可改变部分药物代谢，增加或降低药物疗效，同时可能引发不良反应，严重者甚至危及患者生命。该文将吉尔伯特综合征与常见药物代谢间的相互作用、用药注意事项作一综述。.